Vernalis Research Limited

Scott Murray Weiss

Roger John Gillespie

Joanne Lerpiniere

Suneel Gaur

Gemma Caroline Stratton

Stefania Leonardi

Samantha Jayne Bamford

Claire Elizabeth Dawson

Robert Mark Pratt

Robin Gerald Shepherd

Lars Jacob Stray Knutsen

Allan Fletcher

Richard H P Porter

The use of a compound of formula (I): wherein

Triazol[4,5-d] pyramidine derivatives and their use as purinergic receptor antagonists

Use of a compound of formula (I) wherein Ris selected from alkyl, aryl, alkoxy, aryloxy, 0thioalkyl, thioaryl, CN, halo, NRR, NRCOR, NRCONRR, NRCORand NRSOR; Ris selected from N, O or S-containing heteroaryl groups, wherein the heteroaryl group is attached via an unsaturated carbon atom which is adjacent to one or two N, O or S-heteroatom(s), other than ortho, ortho-disubstituted heteroaryl groups; Ris selected from H, alkyl, COR, CONRR, CONRNRR, CORand SOR; R, Rand Rare independently selected from H, alkyl and aryl or where Rand Rare in an (NRR) group then Rand Rmay be linked to form a heterocyclic ring; Ris selected from alkyl and aryl; R, Rand Rare independently selected from H, alkyl and aryl, or Rand Rmay be linked to form a heterocyclic ring, or where R, Rand Rare in a (CONRNRR) group, Rand Rmay be linked to form a heterocyclic group; and R, is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se. 

Purine derivatives as purinergic receptor antagonists

Triazolo [4,5-d] pyrimidine derivatives and their use as purinergic receptor antagonists

The use of a compound of formula (I): wherein Ris selected from H, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, halogen, CN, NRR, NRCONR, NRCONRR,NRCORand NRSOR; Ris selected from aryl attached via an unsaturated carbon; Ris selected from H, alkyl, COR, COR, CONRR, CONRNRRand SOR; R, Rand Rare independently selected from H, alkyl and aryl or where Rand Rare in an NRRgroup, Rand Rmay be linked to form a heterocyclic group, or where R, Rand Rare in a (CONRNRR) group, Rand Rmay be linked to form a heterocyclic group; and Ris selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly Areceptors, may be beneficial, particularly wherein said disorder is a movement disorder such as Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or for neuroprotection in a subject; compounds of formula (I) for use in therapy; and novel compounds of formula (I) per se 

Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists

The present invention relates to the use of (&plusmn;)-R*,S*)-alpha-2-piperidnyl-2,8-bis(trifluoromethyl)-4-quinolinemthanol and in particular (&minus;)-(11S,2&prime;R)-alpha-2-piperidnyl-2,8-bis(trifluoromethyl)-4-quinolinemthanol in the treatment of disorders in which the reduction of purinergic neurotransmission could be beneficial. The invention relates in particular to adenosine receptors, and particularly adenosine A2a receptors and to the treatment of movement disorders such as Parkinson's disease.

(&minus;)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders

Growing community of inventors

Wokingham, United Kingdom

Scott Murray Weiss